文献速递核素与放射性配体治疗肿瘤 PET/CT

RE-LuPSMA:转移性去势抵抗性前列腺癌[177Lu]Lu-PSMA-617再治疗的2期前瞻性试验

Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA.
PubMed 文献 · J Nucl Med · 2026-05-01

RE-LuPSMA是一项研究者发起的单臂单中心开放标签2期试验,计划入组40例既往接受4-6周期[177Lu]Lu-PSMA-617且PSA下降≥50%后进展的mCRPC患者,再治疗最多6周期(每6周7.4 GBq)。主要终点为再治疗开始后12个月总生存率,设计有80%把握度检测50%与71%的差异。

要点

  • 再治疗对象为既往[177Lu]Lu-PSMA-617治疗获PSA下降≥50%后进展的mCRPC患者。
  • 再治疗前8周内PSMA PET/CT须符合VISION试验标准。
  • 再治疗方案为最多6周期[177Lu]Lu-PSMA-617,每6周7.4 GBq。

核心结论

  • 再治疗研究旨在评估既往[177Lu]Lu-PSMA-617治疗获益后进展患者再次使用该药的疗效与安全性。

研究设计与样本

  • RE-LuPSMA为研究者发起的单臂、单中心、开放标签2期临床试验。
  • 计划入组40例既往完成4-6周期[177Lu]Lu-PSMA-617且PSA下降≥50%后进展的mCRPC患者。
  • 入组要求再治疗首周期计划前8周内PSMA PET/CT符合VISION试验标准。
  • 再治疗最多6周期,每6周7.4 GBq。
  • 主要终点为再治疗开始后12个月总生存率;研究有80%把握度检测50%与71%的差异。

关键数值与推荐

  • 既往[177Lu]Lu-PSMA-617治疗期间任何时点PSA下降≥50%定义为 favorable response。
  • 再治疗前PSMA PET/CT须在计划首周期前8周内符合VISION试验标准。
  • 再治疗方案为[177Lu]Lu-PSMA-617 7.4 GBq每6周,最多6周期。
  • 主要终点为再治疗开始后12个月OS,无效假设50% vs 研究假设71%。
  • 次要终点包括不良事件率、PSA下降≥50%比例、生化PFS(PSA较最低点升高25%且2 ng/mL)、影像学PFS及生活质量变化。

临床怎么用

  • 对既往[177Lu]Lu-PSMA-617治疗获PSA下降≥50%后进展的mCRPC患者,可考虑再治疗评估。
  • 再治疗前需复核PSMA PET/CT是否符合VISION试验标准。

局限性

  • 单臂、单中心、开放标签设计。
  • 计划样本量40例,研究尚在进行中,疗效与安全性结果未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[177Lu]Lu-PSMA-617 radiopharmaceutical therapy has been approved for the treatment of patients with metastatic castration-resistant prostate cancer for up to 6 cycles. Unfortunately, this treatment is not curative and patients experience relapse, even after initially favorable responses. When this occurs, patients have limited treatment options. Readministration of [177Lu]Lu-PSMA-617 in patients who previously benefited from therapy and had limited toxicity seems to be a promising option, with retrospective studies reporting favorable outcomes. Methods: RE-LuPSMA is an investigator-initiated, single-arm, single-center, open-label, phase 2 clinical trial designed to study the efficacy and safety of rechallenge therapy using [177Lu]Lu-PSMA-617 in patients whose disease progressed after responding well to a previous regimen of [177Lu]Lu-PSMA-617. This study plans to enroll 40 patients with progressive metastatic castration-resistant prostate cancer who previously completed 4-6 cycles of [177Lu]Lu-PSMA-617 with a favorable response (i.e., ≥50% decrease in prostate-specific antigen [PSA] level at any point during the first [177Lu]Lu-PSMA-617 regimen). After the first regimen of [177Lu]Lu-PSMA-617, patients must meet VISION trial criteria on a prostate-specific membrane antigen (PSMA) PET/CT scan within 8 wk of the planned first cycle of rechallenge therapy. After enrollment, participants will receive up to 6 additional cycles of [177Lu]Lu-PSMA-617 (7.4 GBq every 6 wk). The primary endpoint is 12-mo overall survival (OS), measured from the start of rechallenge therapy. The study will have 80% power to detect a difference between the null hypothesis of 50% OS at 12 mo and the study hypothesis of 71% OS at 12 mo. Secondary endpoints include adverse-event rates, PSA response rates (proportion of patients with a decrease of 50% or greater in PSA level), biochemical progression-free survival (defined as the time until PSA level increases 25% and 2 ng/mL above the nadir), radiographic progression-free survival, and quality-of-life changes (measured using Functional Assessment of Cancer Therapy-Radionuclide Therapy and Brief Pain Inventory-Short Form). Enrollment began in August 2024, with a planned study duration of 45 mo.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Nikitas J, Holzgreve A, Juarez J, et al. Phase 2 Prospective Trial of Retreatment with [177Lu]Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration-Resistant Prostate Cancer-RE-LuPSMA. J Nucl Med. 2026. PMID: 41679923. doi:10.2967/jnumed.125.271231

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。